BloodbankZ
-
Content Count
20 -
Joined
-
Last visited
-
Country
United States
-
I was wanting to get input on DAT's performed for Transfusion Reaction Investigations. Do you perform them with just IgG, C3d or both? TIA.
-
Remote as in another location within the same hospital outside of the Blood Bank like the ER or OR.
-
I am looking at storing blood products in a remote location for our facility. Just curious what everyone is doing currently? Thanks for the info!
-
We use the Ortho Confidence System and AB plasma as our negative control. That will cover all of your possibility of reactions. Yes you would have to QC the ABD card as well. For Cord study we run the ABD w/Rev (in case the patient is AB POS you need the ctrl) and an IgG card well for the DAT. It may detect weak D but we perform a weak D test on every Rh negative newborn.
-
We use Ortho gel primarily. It states nothing about centrifuge time. We use greiner tubes and they recommend 2000g for 10 min for platelet poor plasma. I am leaning towards the Stat spin express which is 3 minutes at 4000g. As long as it validates I don't see a problem do you?
-
Is there still a good serological centrifuge out there?
BloodbankZ replied to Mabel Adams's topic in Transfusion Services
Check EBAY I picked up a Clay Adams Serofuge there to "revitalize" one of ours. I think it was only $400. -
BankerGirl do you know the g force?
-
-
-
I am looking to cut down our TAT. We currently spin our specimens for 10 minutes. Any suggestions for stat centrifuges? TIA.
-
I am needing some help setting up electronic crossmatch in Meditech. I have everything else in place but can not figure out how to prevent EXM in patients who have mixed field reactions. I am wanting to be able to perform the IS serologically as I understand this is needed per CAP and FDA regulations. Has anyone else experience this. We are currently on version 6.08. Thanks in advance!
-
BloodbankZ changed their profile photo
-
DTT-Treatment of Screening Cells (Daratumumab/Darzalex)
BloodbankZ replied to septima's topic in Transfusion Services
I would say it is due to the DARA. DTT treated cells will eliminate the DARA reactivity and let you be able to rule out everything besides mainly Kell system which DTT denatures. We perform a baseline type and screen and DNA HEA typings on patients before they start. If DTT screen is negative we give K negative cells if patient is antigen negative. -
DTT-Treatment of Screening Cells (Daratumumab/Darzalex)
BloodbankZ replied to septima's topic in Transfusion Services
When I tried to run it in gel I never could get nice clean reactions. Their would always be particulate at the top of the wells. I have seen several tube procedures that are just using so many drops of 4% cell suspensions instead of concentrating their cells and then getting an exact 4:1 ratio with DTT. I have since went to doing it in tube. What kind of steps are you performing? -
-
Thanks so much Eman that is just what I needed. I just couldn't find it.
-
I was wondering if anyone knew of a report that showed incident rate of FDA reportable events per hospital or per other statistic like transfusions, patients, etc... Just looking for a baseline to see how our facility compares to others. I have searched and reached out to other facilities and haven't had any luck. Thanks in advance.
-
DTT-Treatment of Screening Cells (Daratumumab/Darzalex)
BloodbankZ replied to septima's topic in Transfusion Services
Has anybody tried DTT treating reagent red blood cells in MTS gel method? If so are you concentrating your cells before treating or have adjusted your ratio of DTT to the .8% suspension? TIA. -
What are other people's institutions practices on the following. If you have a patient with an anti-D do you need to go ahead and carry out the D antigen typing on the patients rbcs through the IAT phase(weak D testing)? The AABB 18TH ed. Technical Manual states on pg. 327 "When the D type of a patient is determined, a weak D test is not necessary except to assess the red cells of an infant whose mother is at risk of D immunization." It then goes on to say under Identification of Antibodies to Red Cell Antigens pg.401 "Determining the phenotype of the autologous red cells is an important part of antibody identification." We use MTS gel for as our primary method for blood type determination and it states that Most weak D antigen expressions will be detected(which means not all), however partial DVI epitope variant of the D antigen will not be detected with this monoclonal reagent. Not that it really changes how we transfuse the patient but just curious to others procedures/thoughts. Thanks in advance.
